The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for BeOne Medicines's Beneish M-Score or its related term are showing as below:
ONC'
s Beneish M-Score Range Over the Past 10 Years
Min: -13.63 Med: -2.17 Max: 611.4
Current: -2.73
During the past 13 years, the highest Beneish M-Score of BeOne Medicines was 611.40. The lowest was -13.63. And the median was -2.17.
BeOne Medicines Beneish M-Score Related Terms
BeOne Medicines Beneish M-Score Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs RVMD, RPRX, BNTX: Beneish M-Score Comparison
For the Biotechnology subindustry, BeOne Medicines's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of BeOne Medicines for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.925
+
0.528 * 0.9604
+
0.404 * 0.5684
+
0.892 * 1.3744
+
0.115 * 1.2018
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.8504
+
4.679 * -0.086495
-
0.327 * 0.877
=
-2.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(179.273 / (179.273 + 1748.43))
/
(150.026 / (150.026 + 1788.704))
=
0.092998
/
0.077384
=
1.2018
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(513.02 - -31.967
-
1284.834)
/
8553.619
=
-0.086495
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
BeOne Medicines has a M-score of -2.73 suggests that the company is unlikely to be a manipulator.
BeOne Medicines (ONC) has a Beneish M-Score of -2.73 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #282 out of 831 companies in the Biotechnology industry, placing it in the top 33.9%.
Is BeOne Medicines' Beneish M-Score too high?
BeOne Medicines' current Beneish M-Score is -2.73. Based on the distribution chart, BeOne Medicines ranks #282 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Beneish M-Score compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #282 out of 831 companies for Beneish M-Score. This puts BeOne Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Beneish M-Score is -2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $280.00 — trading 23.5% below its estimated fair value. The current Beneish M-Score is -2.73. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Beneish M-Score is -2.73 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Beneish M-Score: -2.73
GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for ONC
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
